Literature DB >> 22340926

Celiac disease and hypothyroidism.

Dan Collins1, Rebecca Wilcox, Muriel Nathan, Richard Zubarik.   

Abstract

BACKGROUND: Celiac disease is more common in patients with hypothyroidism. Malabsorption of levothyroxine has not been studied in this population. We sought to determine if levothyroxine dosing was influenced by the presence and treatment of celiac disease.
METHODS: This retrospective study was conducted at an academic medical center. Cases had hypothyroidism and celiac disease. Controls had hypothyroidism alone and were selected randomly through the endocrinology clinic records. Celiac disease was defined as representative pathology with positive serology. Age, sex, height, weight, body mass index, creatinine, and medical comorbidity were assessed for cases and controls. The levothyroxine dose and weight-based levothyroxine dose necessary to maintain a euthyroid state was evaluated for controls, and before and after celiac disease therapy for cases.
RESULTS: Celiac disease was identified in 152 patients, and 22 patients had concomitant hypothyroidism (14.5%). Seven cases met inclusion criteria. Overall, 200 control patients were identified. The mean celiac disease pretreatment levothyroxine dose and weight-based levothyroxine dose needed to maintain a euthyroid state were higher in cases than in controls (154 μg vs 106 μg, P=.007, and 2.6 μg/kg vs 1.3 μg/kg, P <.001). Doses decreased significantly after treatment of celiac disease (154 μg vs 111 μg, P=.03; and 2.64 μg/kg vs 1.89 μg/kg, P=.04). All cases required at least 125 μg of levothyroxine initially to maintain a euthyroid state.
CONCLUSIONS: Levothyroxine malabsorption likely occurs with hypothyroidism and untreated celiac disease. Absorption may improve after celiac disease treatment. Screening for celiac disease in patients with hypothyroidism requiring elevated levothyroxine doses warrants further investigation. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340926     DOI: 10.1016/j.amjmed.2011.09.003

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

2.  A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.

Authors:  Roberto Vita; Giovanna Saraceno; Francesco Trimarchi; Salvatore Benvenga
Journal:  Endocrine       Date:  2012-08-30       Impact factor: 3.633

3.  Thyroxine softgel capsule in patients with gastric-related T4 malabsorption.

Authors:  Maria Giulia Santaguida; Camilla Virili; Susanna Carlotta Del Duca; Miriam Cellini; Ilenia Gatto; Nunzia Brusca; Corrado De Vito; Lucilla Gargano; Marco Centanni
Journal:  Endocrine       Date:  2015-01-17       Impact factor: 3.633

4.  Myxedema Secondary to Levothyroxine Malabsorption in Newly Diagnosed Celiac Disease.

Authors:  Brandon Wiggins; Kyle T Knight; Fady Banno; Mark Minaudo
Journal:  Cureus       Date:  2022-05-30

Review 5.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

Review 6.  Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance.

Authors:  Anthony Samsel; Stephanie Seneff
Journal:  Interdiscip Toxicol       Date:  2013-12

7.  Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance Project.

Authors:  Marjorie McMillan; Keith S Rotenberg; Kevin Vora; Arnold B Sterman; Lionel Thevathasan; Michael F Ryan; Munish Mehra; Walter Sandulli
Journal:  Drugs R D       Date:  2016-03

8.  The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study.

Authors:  Frank R Ernst; Peri Barr; Riad Elmor; Walter Sandulli; Lionel Thevathasan; Arnold B Sterman; Jessica Goldenberg; Kevin Vora
Journal:  Clin Drug Investig       Date:  2017-01       Impact factor: 2.859

9.  TSH-Suppressive Therapy: A Thorny Issue.

Authors:  Itala Marina Baldini; Cristina Cocino; Sonia Seghezzi; Maria Domenica Cappellini
Journal:  Eur J Case Rep Intern Med       Date:  2017-03-27

Review 10.  Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime.

Authors:  Leonidas H Duntas; Jacqueline Jonklaas
Journal:  Adv Ther       Date:  2019-09-04       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.